Notice of Product Exclusion Extensions: China's Acts, Policies, and Practices Related to Technology Transfer, Intellectual Property, and Innovation
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
In prior notices, the U.S. Trade Representative modified the action in the Section 301 investigation of China's acts, policies, and practices related to technology transfer, intellectual property, and innovation by excluding from additional duties certain medical-care products needed to address the COVID-19 pandemic. Exclusions for medical care products to address COVID-19 were published on December 29, 2020, and subsequently extended. In November 2021, the U.S. Trade Representative determined to extend 81 of the COVID-19 related product exclusions for an additional 6 months. These exclusions are scheduled to expire on May 31, 2022. This notice announces the U.S. Trade Representative's determination to further extend the 81 COVID exclusions for an additional 6 months.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.